Breaking News

Amarin Still Hindered By Lack Of M&A Activity And NCE Designation

By Myriad Equity Stock MarketsNov 21, 2012 02:19AM ET
Amarin Still Hindered By Lack Of M&A Activity And NCE Designation
By Myriad Equity   |  Nov 21, 2012 02:19AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
The market continues to scrutinize every headline that is released about Amarin Corporation (NASDAQ: AMRN), looking for hints about its upcoming launch of Vascepa (isosapent ethyl) in Q1 2013 and high possibility that the company will be acquired in the very near future.

Vascepa, formerly known as AMR101, is a drug that was approved for patients with extremely high levels of triglycerides (specifically those with greater than 500 mg/dL). Vascepa is a highly concentrated capsule containing a specific compound – EPA (eicosapentaenoic acid), that is derived from fish oil. The current prescription “fish oil pill” that dominates the high triglyceride patient population is Lovaza, although the key difference is that it contains both eicosapentaenoic acid and docosahexaenoic acid (DHA).

According to recent statistical data provided by Amarin, their current NDA designation for Vascepa will target up to 4 million in the United States alone, and many more abroad. Lovaza is already targeting this same patient population with great success (bringing in about $1 billion per year for GlaxoSmithKline), which implies that Amarin could be severely undervalued with its current market capitalization of $1.6 billion granted that Vascepa could achieve peak sales on par (or better) than Lovaza in that super-high triglyceride level patient population.

Still, the biggest value potential for Vascepa likes in the patient population with high triglyceride levels that don’t reach the 500 mg/dL threshold. More specifically, these ~36 million patients have triglycerides between 200-500 mg/dL – high, but not high enough to be officially eligible for Lovaza.

While it’s not all that rare to see a biotech stock drop after FDA approval from all the profit-taking, the price action in shares of AMRN was particularly unusual and bearish since the approval date of July 26, 2012. After AMRN made a new 52-week high of $15.96/share in July, the stock reversed dramatically going into August, and failed a recovery rally attempt in September. AMRN never really recovered from the post-approval downward momentum.

The two biggest reasons that the market has soured on Amarin stock recently are simple, but difficult to price into to the actual valuation of the company on the NASDAQ. First, there is the NCE (New Chemical Entity) status of Vascepa – something that the FDA has yet to provide. If Vascepa were designated as a NCE by the FDA it would receive 5 years instead of 3 years of exclusivity on the market.

Since generic competition can be extremely detrimental to the sales revenue of any drug, two years of exclusivity is a big deal. The second major reason that AMRN started going bearish has to do with the widely held belief that Amarin itself was going to be bought by a larger pharmaceutical company following the FDA approval of Vascepa.

We got confirmation in Amarin’s recent third quarter earnings conference call that there is indeed a connection between the NCE status of Vascepa and the potential buyout of Amarin. Due to the uncertainty of Vascepa’s designation by the FDA, and the implications it could have, Amarin and its buyers probably had difficulty setting a potential buyout price.

Many analysts say that the assumption that Vascepa can meet or surpass Lovaza sales once it reaches the market would justify a buyout price of at least $20/share (a minimum of an 85% premium to the current price of the shares), although others are citing much higher potential figures ($30/share or more) given Vascepa’s potential in the much larger 200-500 mg/dL hypertriglyceridemia patient population and its unexplored potential in the lowering of bad cholesterols.

As patient as Amarin investors have been throughout the NCE ordeal, and in anticipation of a buyout of the company, we still have no official word form the FDA. On the bright side, we do know that there are pharmaceutical companies that are still very interested in the acquisition of Amarin. AstraZeneca was one name that popped up weeks ago, and we recently heard that Teva Pharmaceuticals was talking to Amarin as well. Both of these pharmaceutical companies are cash-rich, but are suffering from weakness in their pipelines. This would make Vascepa a perfect addition for them due to its price, and enormous potential in a drug market that is expected to grow due to an aging of the US population.

Investors who buy AMRN can hope for a buyout at premium prices in the near term, although they must also grapple with the possibility that Amarin will market Vascepa alone. Wall Street steeply discounts AMRN due to the high chance that Vascepa will launch under Amarin’s management in the expected timeframe (some time in Q1 2013), although it’s also true that Vascepa’s entry into the market does not eliminate the possibility of an acquisition. This doesn’t mention that possibility that Amarin finds its own success without any help in due time.
Amarin Still Hindered By Lack Of M&A Activity And NCE Designation

Related Articles

Amarin Still Hindered By Lack Of M&A Activity And NCE Designation

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Are you sure you want to delete this chart?
Write your thoughts here
Replace the attached chart with a new chart ?
Post also to:
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Post 1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email